Monte Rosa Therapeutics, Inc.

Is Monte Rosa Therapeutics, Inc. overvalued or undervalued?

As of October 17, 2025, Monte Rosa Therapeutics, Inc. is considered fairly valued with a P/E ratio of 50 and a PEG ratio of 0.48, despite outperforming the S&P 500 with an 83.06% return over the past year.

As of 17 October 2025, the valuation grade for Monte Rosa Therapeutics, Inc. has moved from very attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 50, while the Price to Book Value is 1.12, and the PEG Ratio is 0.48, indicating that the stock may not be significantly undervalued despite its previous attractive rating.<BR><BR>In comparison with peers, Monte Rosa's P/E ratio of 12.27 is notably higher than MeiraGTx Holdings Plc, which has a P/E of -3.82, and 23andMe Holding Co., which has a P/E of -0.75, suggesting that Monte Rosa is relatively more valued in the market. Over the past year, Monte Rosa has delivered a return of 83.06%, significantly outperforming the S&P 500's return of 14.08%, reinforcing the notion that the stock is currently fairly valued in light of its recent performance.

Is Monte Rosa Therapeutics, Inc. technically bullish or bearish?

As of August 1, 2025, Monte Rosa Therapeutics, Inc. shows a mildly bearish trend despite strong recent performance, with a 41.72% weekly return and 51.97% monthly return, while year-to-date it is down 0.14% compared to the S&P 500's 12.22% gain.

As of 1 August 2025, the technical trend for Monte Rosa Therapeutics, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a daily moving average indicating bearishness, while the weekly MACD and KST remain bullish. The Bollinger Bands are bullish across both weekly and monthly time frames, but the overall sentiment is tempered by the daily indicators. <BR><BR>In terms of multi-period returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 41.72% and 51.97% compared to the S&P's 1.05% and 2.33%, respectively. However, year-to-date, the stock is slightly down at -0.14%, while the S&P 500 has gained 12.22%.

How big is Monte Rosa Therapeutics, Inc.?

As of Jun 18, Monte Rosa Therapeutics, Inc. has a market capitalization of 281.10 million and reported net sales of 159.50 million with a net profit of 6.15 million over the latest four quarters. The company's balance sheet shows shareholder's funds of 222.94 million and total assets of 438.73 million.

As of Jun 18, Monte Rosa Therapeutics, Inc. has a market capitalization of 281.10 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 159.50 million for the latest four quarters and a net profit of 6.15 million during the same period.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of 222.94 million and total assets of 438.73 million.

What does Monte Rosa Therapeutics, Inc. do?

Monte Rosa Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $85 million and a net profit of $47 million. It has a market cap of $281.10 million and key metrics include a P/E ratio of 50.00 and a return on equity of 2.24%.

Overview: <BR>Monte Rosa Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 85 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 47 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 281.10 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 50.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.17 <BR>Return on Equity: 2.24% <BR>Price to Book: 1.02 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Monte Rosa Therapeutics, Inc.?